Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 193Carcinoma, Non-Small-Cell Lung 160Ovarian Neoplasms 96Lung Neoplasms 58Fallopian Tube Neoplasms 57Neoplasms 50Triple Negative Breast Neoplasms 36Neoplasm Metastasis 36Esophageal Neoplasms 22Carcinoma, Ovarian Epithelial 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Stomach Neoplasms 20Squamous Cell Carcinoma of Head and Neck 20Head and Neck Neoplasms 19Endometrial Neoplasms 19Adenocarcinoma of Lung 17Melanoma 15Breast Neoplasms, Male 15Urinary Bladder Neoplasms 13Carcinoma 12Uterine Cervical Neoplasms 11Recurrence 11Carcinoma, Squamous Cell 11Brenner Tumor 11Adenocarcinoma Of Esophagus 10Small Cell Lung Carcinoma 9Peritoneal Neoplasms 9Esophageal Squamous Cell Carcinoma 9Adenocarcinoma, Bronchiolo-Alveolar 9Prostatic Neoplasms 8

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Uterine Corpus Carcinoma × Paclitaxel × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡